Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;33(21):e2007421.
doi: 10.1002/adma.202007421. Epub 2021 Apr 15.

Materials for Improving Immune Cell Transfection

Affiliations
Review

Materials for Improving Immune Cell Transfection

Arun R K Kumar et al. Adv Mater. 2021 May.

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy holds great promise for preventing and treating deadly diseases such as cancer. However, it remains challenging to transfect and engineer primary immune cells for clinical cell manufacturing. Conventional tools using viral vectors and bulk electroporation suffer from low efficiency while posing risks like viral transgene integration and excessive biological perturbations. Emerging techniques using microfluidics, nanoparticles, and high-aspect-ratio nanostructures can overcome these challenges, and on top of that, provide universal and high-throughput cargo delivery. Herein, the strengths and limitations of traditional and emerging materials for immune cell transfection, and commercial development of these tools, are discussed. To enhance the characterization of transfection techniques and uptake by the clinical community, a list of in vitro and in vivo assays to perform, along with relevant protocols, is recommended. The overall aim, herein, is to motivate the development of novel materials to meet rising demand in transfection for clinical CAR-T cell manufacturing.

Keywords: chimeric antigen receptor T-cell therapy; high-aspect-ratio nanostructures; microfluidics; nanoparticles; transfection techniques.

PubMed Disclaimer

References

    1. J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. M. Parkin, M. Piñeros, A. Znaor, F. Bray, Int. J. Cancer 2019, 144, 1941.
    1. J. Schüz, C. Espina, C. P. Wild, Mol. Oncol. 2019, 13, 567.
    1. S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, N. Engl. J. Med. 2014, 371, 1507.
    1. a) X. Dai, Y. Mei, D. Cai, W. Han, Biotechnol. Adv. 2019, 37, 239;
    1. b) A. Mullard, Nat. Rev. Drug Discovery. 2021, 20, 166.

Substances

LinkOut - more resources